Stockscreener 앱 받기
0.957
2.12%
0.0199
Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스
Total debt per share of Heron Therapeutics Inc – LSE:0J4V - TradingView — Track All Markets
Pullback Watch: Can Heron Therapeutics Inc expand into new markets2026 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Heron Therapeutics (HRTX) CEO exercises 62,500 RSUs into common stock - Stock Titan
Earnings Miss: How does Heron Therapeutics Inc compare to its peersQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Heron Therapeutics Executive Employment Agreements: Key Terms, Termination, and Restrictive Covenants Explained - Minichart
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus - TipRanks
Heron Therapeutics (NASDAQ: HRTX) revises executive severance and CIC - Stock Titan
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Analysts - marketbeat.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of “Hold” by Analysts - Defense World
HRTX Stock Price, Quote & Chart | HERON THERAPEUTICS INC (NASDAQ:HRTX) - ChartMill
Q1 Earnings Forecast for HRTX Issued By Northland Securities - MarketBeat
Moving Averages: How does Heron Therapeutics Inc compare to its peersWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Wall Street Recap: How does Heron Therapeutics Inc compare to its peersTrade Entry Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Vanguard realigns holdings; Heron Therapeutics (HRTX) ownership shown as 0 - Stock Titan
What is Northland Securities' Estimate for HRTX Q3 Earnings? - MarketBeat
If You Invested $1,000 in Heron Therapeutics Inc (HRTX) - Stock Titan
Market Trends: Is Heron Therapeutics Inc stock technically oversold2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Clearline Capital LP Increases Holdings in Heron Therapeutics, Inc. $HRTX - MarketBeat
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HRTX SEC FilingsHeron Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citigroup Inc. Increases Stock Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Signals Profitable Growth After Strong Quarter - TipRanks
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q4 2025 Earnings Conference - 富途牛牛
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings - MarketBeat
What is Northland Securities' Forecast for HRTX Q1 Earnings? - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
HRTX Should I Buy - Intellectia AI
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for HRTX Q1 Earnings? - MarketBeat
HRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Heron (HRTX) Q4 2025 Earnings Call Transcript - AOL.com
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target - TipRanks
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment - MSN
Heron Therapeutics Q4 Earnings Call Highlights - MarketBeat
Heron Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-02-26 - Seeking Alpha
Key facts: Heron Therapeutics projects $173-$183M revenue by 2026; ZYNRELEF adoption rises; credit facilities expanded - TradingView
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Heron Therapeutics, Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q4 2025 reports strong growth By Investing.com - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
HRTX: 2025 net revenue rose 7.4% to $154.9M, with strong Acute Care growth and positive EBITDA - TradingView
HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings - Quiver Quantitative
Heron Therapeutics: Q4 Earnings Snapshot - Citizen Tribune
Heron Therapeutics: Fourth Quarter Earnings Overview - Bitget
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report - TradingView
Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort - TradingView
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
HRTX: 2025 net revenue rose 7.4% to $154.9M, driven by Acute Care growth and new CMS J-Codes - TradingView
2.68%
0.34%
자본화:
|
볼륨(24시간):